Biodexa Pharmaceuticals (BDRX) Accounts Payables (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Accounts Payables of $3.4 million for Q4 2025, up 82.64% sequentially from $1.9 million in Q2 2025, and down 23.4% YoY from $4.5 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Accounts Payables (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Accounts Payables for 13 years, with the latest figure at $3.4 million in Q4 2025.
- Quarterly Accounts Payables fell 23.4% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.4 million (down 23.4% YoY) and the FY2025 annual result came in at $3.4 million, down 24.07% from the prior year.
- Accounts Payables rose to $3.4 million in Q4 2025 per BDRX's latest filing, from $1.9 million in the prior quarter.
- Over five years, Accounts Payables peaked at $4.5 million in Q4 2024 and troughed at $1.5 million in Q4 2021.
- A 5-year average of $2.3 million and a median of $2.0 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables tumbled 43.41% in 2022, then surged 192.22% in 2024.
- Over 5 years, Accounts Payables stood at $1.5 million in 2021, then advanced by 15.3% to $1.7 million in 2022, then dropped by 9.32% to $1.5 million in 2023, then soared by 192.22% to $4.5 million in 2024, then decreased by 23.4% to $3.4 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $3.4 million, $1.9 million, and $4.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | 3.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.45 Mn |
| Jun 30, 2025 | 1.89 Mn |
| Dec 31, 2024 | 4.50 Mn |
| Jun 30, 2024 | 2.13 Mn |
| Dec 31, 2023 | 1.54 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Dec 31, 2022 | 1.70 Mn |
| Jun 30, 2022 | 1.61 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Jun 30, 2021 | 2.85 Mn |
| Dec 31, 2020 | 1.62 Mn |
| Jun 30, 2020 | 3.46 Mn |
| Dec 31, 2019 | 5.78 Mn |
| Jun 30, 2019 | 3.25 Mn |
| Dec 31, 2018 | 2.71 Mn |
| Jun 30, 2018 | 4.69 Mn |
| Dec 31, 2017 | 10.62 Mn |
| Jun 30, 2017 | 8.49 Mn |
| Dec 31, 2016 | 10.45 Mn |
| Jun 30, 2016 | 8.32 Mn |